US Bancorp DE cut its position in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 0.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,736 shares of the medical instruments supplier’s stock after selling 93 shares during the quarter. US Bancorp DE’s holdings in West Pharmaceutical Services were worth $7,654,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Planned Solutions Inc. bought a new position in shares of West Pharmaceutical Services in the fourth quarter valued at $39,000. Addison Advisors LLC boosted its position in shares of West Pharmaceutical Services by 37.9% in the third quarter. Addison Advisors LLC now owns 142 shares of the medical instruments supplier’s stock valued at $53,000 after acquiring an additional 39 shares during the period. Livforsakringsbolaget Skandia Omsesidigt boosted its position in shares of West Pharmaceutical Services by 90.0% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 190 shares of the medical instruments supplier’s stock valued at $67,000 after acquiring an additional 90 shares during the period. Lindbrook Capital LLC boosted its position in shares of West Pharmaceutical Services by 46.0% in the fourth quarter. Lindbrook Capital LLC now owns 235 shares of the medical instruments supplier’s stock valued at $83,000 after acquiring an additional 74 shares during the period. Finally, Tompkins Financial Corp bought a new stake in shares of West Pharmaceutical Services in the fourth quarter valued at about $89,000. 93.90% of the stock is owned by institutional investors.
Insider Activity at West Pharmaceutical Services
In related news, CAO Chad Winters sold 815 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $358.82, for a total value of $292,438.30. Following the completion of the transaction, the chief accounting officer now owns 1,309 shares in the company, valued at approximately $469,695.38. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of the stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the sale, the chief executive officer now owns 152,908 shares of the company’s stock, valued at approximately $56,063,718.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Chad Winters sold 815 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $358.82, for a total transaction of $292,438.30. Following the sale, the chief accounting officer now directly owns 1,309 shares of the company’s stock, valued at approximately $469,695.38. The disclosure for this sale can be found here. Insiders sold a total of 68,834 shares of company stock worth $25,215,392 in the last quarter. 0.53% of the stock is owned by insiders.
West Pharmaceutical Services Stock Up 0.9 %
WST stock opened at $331.66 on Tuesday. The company has a quick ratio of 1.95, a current ratio of 2.61 and a debt-to-equity ratio of 0.03. The company has a market cap of $24.16 billion, a PE ratio of 43.75, a price-to-earnings-growth ratio of 5.86 and a beta of 1.05. West Pharmaceutical Services, Inc. has a 52 week low of $310.42 and a 52 week high of $415.73. The business has a 50-day simple moving average of $372.40 and a 200 day simple moving average of $364.17.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last posted its earnings results on Thursday, April 25th. The medical instruments supplier reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.29 by $0.27. The firm had revenue of $695.40 million during the quarter, compared to analysts’ expectations of $670.62 million. West Pharmaceutical Services had a net margin of 19.42% and a return on equity of 20.57%. The business’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.98 earnings per share. Sell-side analysts anticipate that West Pharmaceutical Services, Inc. will post 7.76 EPS for the current fiscal year.
West Pharmaceutical Services Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, August 7th. Stockholders of record on Wednesday, July 31st will be issued a $0.20 dividend. The ex-dividend date is Wednesday, July 31st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.24%. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 10.55%.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on the stock. UBS Group reduced their target price on shares of West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating for the company in a research report on Friday, February 16th. KeyCorp boosted their price target on West Pharmaceutical Services from $440.00 to $470.00 and gave the company an “overweight” rating in a research note on Tuesday, February 13th. StockNews.com downgraded West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Friday, February 16th. Finally, Jefferies Financial Group raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and boosted their price target for the company from $323.00 to $536.00 in a research note on Wednesday, February 7th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $435.20.
Get Our Latest Research Report on West Pharmaceutical Services
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
See Also
Receive News & Ratings for West Pharmaceutical Services Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for West Pharmaceutical Services and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
